10-Q: Madrigal Pharmaceuticals Reports Strong Rezdiffra Sales

Madrigal Pharmaceuticals, Inc. announced significant revenue growth for Rezdiffra, its MASH treatment, following FDA and EC approvals, while also expanding its pipeline with a new GLP-1 receptor agonist.

Summary

• Product revenue, net, for the three months ended September 30, 2025, increased by 362% to $287.3 million, compared to $62.2 million for the same period in 2024.
• Product revenue, net, for the nine months ended September 30, 2025, increased by 730% to $637.3 million, compared to $76.8 million for the same period in 2024.
• Net loss for the three months ended September 30, 2025, was $(114.2) million, compared to $(107.0) million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $(229.7) million, a significant reduction from $(406.5) million in the prior year.
• Cash, cash equivalents, restricted cash, and marketable securities totaled $1,114.7 million as of September 30, 2025, up from $931.3 million as of December 31, 2024.
• Rezdiffra received conditional marketing authorization from the European Commission in August 2025 and was launched in Germany in September 2025.
• Entered into a senior secured credit facility in July 2025, providing up to $500.0 million, with an initial term loan of $350.0 million funded.
• Acquired an exclusive global license for MGL-2086, a preclinical oral small molecule GLP-1 receptor agonist, from CSPC Pharmaceutical Group Limited in July 2025, with a $120.0 million upfront payment made in October 2025.
• A new U.S. patent covering Rezdiffra's commercial weight-threshold dosing regimen was issued on August 5, 2025, providing protection until February 2045.

Sentiment

Score: 8

Explanation: The company demonstrated exceptional revenue growth for its key product, Rezdiffra, following successful market entry in the US and expansion into Europe. The in-licensing of a new GLP-1 asset also strengthens its long-term pipeline. While losses continue and expenses rise, this is expected for a company in this stage of commercialization and development, and the strong cash position provides a solid runway. These factors collectively point to strong future growth potential and market leadership.

Positives

• Product revenue, net, for Q3 2025 surged by 362% to $287.3 million, demonstrating strong market acceptance for Rezdiffra.
• Year-to-date product revenue, net, for Q3 2025 increased by 730% to $637.3 million, reflecting robust commercialization efforts.
• Net loss for the nine months ended September 30, 2025, significantly decreased to $(229.7) million from $(406.5) million in the prior year, indicating improved financial performance.
• Rezdiffra received conditional marketing authorization from the European Commission in August 2025 and was successfully launched in Germany in September 2025, expanding its global market reach.
• Rezdiffra is the first and only medication approved by both the FDA and EC for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
• Secured a new senior secured credit facility of up to $500.0 million in July 2025, with an initial $350.0 million funded, enhancing liquidity and financial flexibility.
• In-licensed MGL-2086, a preclinical oral GLP-1 receptor agonist, from CSPC, diversifying the pipeline and targeting another significant metabolic disease area.
• A new U.S. patent for Rezdiffra's dosing regimen was issued, extending intellectual property protection until February 2045.

Negatives

• Continued to report a net loss of $(114.2) million for the three months ended September 30, 2025.
• Operating expenses increased significantly, with cost of sales up 742% for the quarter, research and development up 153%, and selling, general and administrative expenses up 94%.
• Interest income decreased by 21% for the three months ended September 30, 2025, primarily due to lower interest rates.
• Interest expense increased by 103% for the three months ended September 30, 2025, due to a higher average outstanding principal balance from the new financing agreement.
• Incurred a $2.8 million loss on extinguishment of debt related to the repayment of the Hercules Loan Facility.
• A $120.0 million upfront expense for the CSPC License Agreement was recognized in research and development, contributing to increased R&D costs.

Risks

• Uncertainty of product development and commercialization for new products.
• Dependence on key personnel.
• Uncertainty of market acceptance of products and product reimbursement.
• Product liability risks.
• Uncertain protection of proprietary technology.
• Potential inability to raise additional financing necessary for development and commercialization.
• Compliance with FDA, European Medicines Agency, and other government regulations.
• Future long-term liquidity requirements will be substantial and depend on effective commercialization of Rezdiffra, geographic expansion, clinical trials, strategic transactions, and compliance with loan covenants.
• Inability to obtain sufficient funds on acceptable terms could have a material adverse effect on business, results of operations, and financial condition.
• Exposure to risks related to changes in foreign currency exchange rates (U.S. dollar, euro, Swiss franc) as operations expand into Europe.
• Potential for changes in global trade or other economic policies, including tariffs and inflation, to adversely affect the business.
• Competition in a rapidly changing environment.
• New risk factors may emerge, and the impact of all risk factors cannot be fully assessed.

Future Outlook

The company expects to incur losses until it generates sufficient revenue from Rezdiffra and any other approved products. Available cash resources are believed to be sufficient to fund operations past one year from the financial statements' issuance. Future long-term liquidity requirements will be substantial, depending on Rezdiffra's commercialization, geographic expansion, clinical trials, strategic transactions, and compliance with loan covenants. The company may need to raise additional capital through debt or equity financings, collaborations, partnerships, or other strategic transactions. The MAESTRO-NASH OUTCOMES trial results are expected in 2027, and confirmatory outcomes data from the MAESTRO-NASH trial are expected in 2028. Clinical development of MGL-2086 is expected to begin in the first half of 2026.

Management Comments

• Rezdiffra is the first and only medication approved by both the FDA and EC for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3 fibrosis).
• We are also evaluating Rezdiffra in patients with compensated MASH cirrhosis (consistent with F4c fibrosis) in our MAESTRO-NASH OUTCOMES trial, that, if successful, could expand the eligible patient population for Rezdiffra.
• We continue to focus our efforts on educating healthcare providers and patients on the risks of MASH and the potential clinical benefits and appropriate use of Rezdiffra.
• We are also supporting the creation of care pathways for patients at physician offices, driving breadth and depth of Rezdiffra prescribers and engaging with payors to support patient access to therapy.
• We plan to selectively in-license or acquire rights to programs at all stages of development to take advantage of our drug development and commercial capabilities.
• With a goal of building a well-balanced and diversified portfolio, we assess a variety of factors for potential product candidates and technologies.
• We intend to be opportunistic in our business development activities to achieve our long-term strategic goals.

Industry Context

MASH (formerly NASH) represents a significant unmet medical need, being a leading cause of liver transplantation in women and the second leading cause overall in the U.S., with rapid growth in Europe. Rezdiffra's status as the first and only FDA and EC-approved medication for noncirrhotic MASH with moderate to advanced liver fibrosis positions the company as a pioneer in this therapeutic area. The strategic in-licensing of MGL-2086, a GLP-1 receptor agonist, aligns with the broader industry trend of targeting metabolic diseases with innovative therapies, potentially diversifying the company's portfolio beyond THR-beta agonists. The company's focus on physician and patient education, along with payor engagement, is critical for establishing market presence and securing reimbursement in this nascent but high-potential market.

Comparison to Industry Standards

• Rezdiffra is the first and only medication approved by both the FDA and EC for noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3 fibrosis), setting a new standard of care in this specific patient population.
• The MAESTRO-NASH trial demonstrated statistically significant improvement compared to placebo on MASH resolution with no worsening of fibrosis and an improvement in fibrosis by at least one stage, which are critical endpoints for regulatory approval in this disease, aligning with high industry standards for clinical efficacy.
• The strategy to expand the eligible patient population through the MAESTRO-NASH OUTCOMES trial for compensated MASH cirrhosis (F4c fibrosis) is a common industry approach to maximize market potential for approved therapies, similar to how other pharmaceutical companies pursue label expansions.
• The in-licensing of MGL-2086, a GLP-1 receptor agonist, places the company in a highly competitive and rapidly evolving therapeutic area. While MGL-2086 is preclinical and specifically targeted for MASH, it will compete with established GLP-1 agonists like Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Zepbound and Mounjaro, which currently dominate the diabetes and weight loss markets and are also being explored for MASH, indicating a high bar for differentiation and clinical outcomes.

Management Changes

Corporate Governance

Legal Proceedings

• Not party to any material legal proceedings.

Related Party Transactions

• Sale of warrants to related parties in equity offerings, exercise of common stock options, and restricted stock vesting, net of transaction costs, occurred in 2024.
• Proceeds from related parties warrants, exercise of common stock options, net of transaction costs, were recorded in 2024 cash flows.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong Rezdiffra sales, market expansion, and pipeline growth. Dilution risk from potential future capital raises. Impact from director changes.
• Employees: Increased headcount to support commercialization efforts. New inducement plan for equity grants.
• Customers (patients/physicians): Increased access to Rezdiffra in Europe. Continued education on MASH and Rezdiffra. Potential for expanded indications.
• Suppliers/Creditors: Continued demand for active pharmaceutical ingredients ($187.6 million in obligations). New credit facility provides financial stability.
• Regulatory Bodies: Continued compliance with FDA and EC requirements for Rezdiffra and future products. Ongoing clinical trials for further approvals.

Next Steps

• Continue commercialization efforts for Rezdiffra in the U.S. and expand operations in Europe.
• Generate confirmatory outcomes data from the MAESTRO-NASH trial (expected 2028) to support full FDA approval for noncirrhotic MASH.
• Generate outcomes data from the MAESTRO-NASH OUTCOMES trial (expected 2027) to potentially expand Rezdiffra's eligible patient population to compensated MASH cirrhosis (F4c fibrosis).
• Initiate clinical development of MGL-2086 in the first half of 2026.
• Selectively in-license or acquire rights to programs at all stages of development to diversify the portfolio.
• Educate healthcare providers and patients on MASH risks and Rezdiffra's potential clinical benefits and appropriate use.
• Support the creation of care pathways for patients at physician offices and engage with payors to support patient access to therapy.
• Maintain compliance with the liquidity covenant in the Financing Agreement.
• Potentially raise additional capital through debt or equity financings, collaborations, partnerships, or other strategic transactions to meet future long-term liquidity requirements.

Key Dates

Recommendation

The company has demonstrated exceptional commercial execution with Rezdiffra, achieving significant revenue growth in both the US and now expanding into Europe with EC approval and a German launch. This establishes Rezdiffra as a first-in-class treatment for a high unmet medical need. The in-licensing of MGL-2086, a GLP-1 receptor agonist, strategically diversifies the pipeline into another high-growth metabolic disease area. While the company continues to incur losses, this is typical for a biotech in its early commercial phase, and the strong cash position, bolstered by the new credit facility, provides ample runway for ongoing development and commercialization. The new patent protection for Rezdiffra further de-risks the asset. These factors collectively point to strong future growth potential and market leadership.

Keywords

MASH, Rezdiffra, resmetirom, biopharmaceutical, liver disease, FDA approval, EC approval, GLP-1, MGL-2086, clinical trials, MAESTRO-NASH, corporate finance, drug development, commercialization, pharmaceuticals, metabolic dysfunction-associated steatohepatitis, THR-beta agonist, patent protection